Emily A Downs1, D Scott Lim1, Mike Saji1, Gorav Ailawadi1. 1. 1 Department of Surgery, Division of Thoracic and Cardiovascular Surgery, 2 Department of Medicine, Division of Cardiovascular Medicine, University of Virginia, Virginia, USA.
Abstract
BACKGROUND: Many patients affected with mitral valve regurgitation suffer from multiple comorbidities. The MitraClip device provides a safe means of transcatheter valve repair in patients with suitable mitral valve anatomy who are at prohibitive risk for surgery. We describe our early procedural outcomes and present a summary of the current state of MitraClip technology in the United States. METHODS: We performed a retrospective chart review of initial high-risk or inoperable patients who underwent MitraClip placement at our institution after completion of the EVEREST II study. We examined the primary outcome of 30-day mortality, and secondary outcomes included extent of reduction of mitral regurgitation (MR), New York Heart Association (NYHA) functional class improvement, length of stay, and major complications. RESULTS: A total of 115 high-risk patients (mean Society of Thoracic Surgeons predicted risk of mortality 9.4%±6.1%) underwent the MitraClip procedure at our institution between March 2009 and April 2014. Co-morbidities including coronary artery disease (67.8%), pulmonary disease (39.1%) and previous cardiac surgery (44.3%) were common. The device was placed successfully in all patients with a 30-day mortality of 2.6%. All patients demonstrated 3+ or 4+ MR on preoperative imaging, and 80.7% of patients had trace or 1+ MR at hospital discharge. NYHA class improved substantially, with 79% of patients exhibiting class III or IV symptoms pre-procedure and 81% reporting class I or II symptoms at one month follow-up. CONCLUSIONS: The MitraClip procedure provides a safe alternative to surgical or medical management for high-risk patients with MR and suitable valve anatomy. A comprehensive heart team approach is essential, with surgeons providing critical assessment of patient suitability for surgery versus percutaneous therapy as well as performance of the valve procedure.
BACKGROUND: Many patients affected with mitral valve regurgitation suffer from multiple comorbidities. The MitraClip device provides a safe means of transcatheter valve repair in patients with suitable mitral valve anatomy who are at prohibitive risk for surgery. We describe our early procedural outcomes and present a summary of the current state of MitraClip technology in the United States. METHODS: We performed a retrospective chart review of initial high-risk or inoperable patients who underwent MitraClip placement at our institution after completion of the EVEREST II study. We examined the primary outcome of 30-day mortality, and secondary outcomes included extent of reduction of mitral regurgitation (MR), New York Heart Association (NYHA) functional class improvement, length of stay, and major complications. RESULTS: A total of 115 high-risk patients (mean Society of Thoracic Surgeons predicted risk of mortality 9.4%±6.1%) underwent the MitraClip procedure at our institution between March 2009 and April 2014. Co-morbidities including coronary artery disease (67.8%), pulmonary disease (39.1%) and previous cardiac surgery (44.3%) were common. The device was placed successfully in all patients with a 30-day mortality of 2.6%. All patients demonstrated 3+ or 4+ MR on preoperative imaging, and 80.7% of patients had trace or 1+ MR at hospital discharge. NYHA class improved substantially, with 79% of patients exhibiting class III or IV symptoms pre-procedure and 81% reporting class I or II symptoms at one month follow-up. CONCLUSIONS: The MitraClip procedure provides a safe alternative to surgical or medical management for high-risk patients with MR and suitable valve anatomy. A comprehensive heart team approach is essential, with surgeons providing critical assessment of patient suitability for surgery versus percutaneous therapy as well as performance of the valve procedure.
Authors: Ted Feldman; Hal S Wasserman; Howard C Herrmann; William Gray; Peter C Block; Patrick Whitlow; Fred St Goar; Leonardo Rodriguez; Frank Silvestry; Allan Schwartz; Timothy A Sanborn; Jose A Condado; Elyse Foster Journal: J Am Coll Cardiol Date: 2005-10-19 Impact factor: 24.094
Authors: Vuyisile T Nkomo; Julius M Gardin; Thomas N Skelton; John S Gottdiener; Christopher G Scott; Maurice Enriquez-Sarano Journal: Lancet Date: 2006-09-16 Impact factor: 79.321
Authors: O Alfieri; F Maisano; M De Bonis; P L Stefano; L Torracca; M Oppizzi; G La Canna Journal: J Thorac Cardiovasc Surg Date: 2001-10 Impact factor: 5.209
Authors: Donald D Glower; Saibal Kar; Alfredo Trento; D Scott Lim; Tanvir Bajwa; Ramon Quesada; Patrick L Whitlow; Michael J Rinaldi; Paul Grayburn; Michael J Mack; Laura Mauri; Patrick M McCarthy; Ted Feldman Journal: J Am Coll Cardiol Date: 2014-07-15 Impact factor: 24.094
Authors: Laura Mauri; Elyse Foster; Donald D Glower; Patricia Apruzzese; Joseph M Massaro; Howard C Herrmann; James Hermiller; William Gray; Andrew Wang; Wesley R Pedersen; Tanvir Bajwa; John Lasala; Reginald Low; Paul Grayburn; Ted Feldman Journal: J Am Coll Cardiol Date: 2013-05-09 Impact factor: 24.094
Authors: D Scott Lim; Matthew R Reynolds; Ted Feldman; Saibal Kar; Howard C Herrmann; Andrew Wang; Patrick L Whitlow; William A Gray; Paul Grayburn; Michael J Mack; Donald D Glower Journal: J Am Coll Cardiol Date: 2013-10-31 Impact factor: 24.094